Liver fibrosis, characterized by excessive scar tissue formation resulting from chronic liver injury, often precedes cirrhosis and liver failure, conditions with few effective treatments. Central to the progression of fibrosis is mitochondrial dysfunction, especially disruptions in the electron transport chain (ETC), which impacts cellular energy production and oxidative stress dynamics. Sun et al. have delved into the molecular choreography that sustains mitochondrial integrity amid fibrogenic stimuli, identifying NEK7 as a key regulatory node. Their research sheds light on a sophisticated control mechanism where NEK7 physically and functionally couples to SDHB, a catalytic subunit of Complex II in the ETC, to preserve electron flux and reduce mitochondrial reactive oxygen species (ROS) accumulation.

At the heart of this research is the assessment of how NEK7 influences the respiratory chain’s efficiency. Complex II, or succinate dehydrogenase, serves a dual function in the tricarboxylic acid (TCA) cycle and the ETC, making its regulation crucial for cellular metabolism. By interacting with SDHB, NEK7 stabilizes Complex II function, ensuring that electrons are effectively transported without premature leakage that triggers oxidative damage. This nuanced regulation helps maintain ATP synthesis and controls the redox environment within hepatic cells, a critical factor in preventing the activation of fibrotic pathways.

The investigative team employed an array of biochemical and cell biology techniques to delineate the interaction between NEK7 and SDHB. Co-immunoprecipitation and proximity ligation assays confirmed the physical coupling of these proteins in mitochondria isolated from hepatic tissues. Functional assays incorporating respiratory flux measurements and mitochondrial membrane potential assessments demonstrated that the presence of NEK7 preserves mitochondrial efficiency and prevents electron transport derailment under stress conditions. These findings underscore the protective role of NEK7 in maintaining mitochondrial homeostasis, essential for healthy liver function.

Intriguingly, loss-of-function experiments in which NEK7 expression was suppressed revealed exacerbated mitochondrial dysfunction. Knockdown models showcased diminished Complex II activity, heightened ROS production, and a marked increase in markers of fibrogenesis. This phenotype correlated with amplified activation of hepatic stellate cells (HSCs), the principal effectors of fibrotic scarring. Conversely, overexpressing NEK7 ameliorated mitochondrial impairment and restrained fibrotic cascades, highlighting the therapeutic potential of targeting NEK7 pathways.

Further mechanistic insights uncovered by the study include how NEK7 modulates the conformation of SDHB, thereby optimizing its electron transfer capabilities. Structural analyses suggest NEK7-mediated phosphorylation events may induce allosteric modifications in SDHB, enhancing its affinity for electron donors and acceptors within Complex II. Such molecular fine-tuning represents a sophisticated example of post-translational regulation in mitochondrial bioenergetics, which could be exploited for drug development.

Given the centrality of mitochondrial dysfunction in a wide range of chronic diseases, these findings hold implications that extend beyond liver pathology. By establishing NEK7 as a mitochondrial quality control factor, the study bridges the fields of cellular signaling and metabolism, providing a conceptual framework for investigating kinase-mediated regulation of energy homeostasis in other organs susceptible to fibrosis, including the heart, kidney, and lung.

Moreover, this research propels NEK7 into the spotlight as a promising biomarker and therapeutic target. The ability of NEK7 to counterbalance oxidative stress and maintain ETC function positions it as a molecular switch that could be modulated pharmacologically to halt or reverse fibrotic progression. Small molecules or gene therapy approaches aimed at enhancing NEK7 activity might thus represent innovative treatments for liver fibrosis and potentially other fibrotic disorders.

The study’s findings were corroborated in vivo using mouse models of liver fibrosis induced by chronic injury. Mice deficient in NEK7 exhibited severe impairment in respiratory chain function, increased fibrotic deposition, and worsened liver histopathology compared to controls. Treatment with agents that restored NEK7 activity ameliorated these pathological changes, affirming the kinase’s critical role in vivo and reinforcing its therapeutic relevance.

Additionally, the authors explored the link between NEK7-SDHB interaction and inflammatory signaling pathways. They reported that preserving respiratory chain integrity via NEK7 prevents activation of inflammasomes, multiprotein complexes implicated in sterile inflammation and fibrosis. This cross-talk between mitochondrial homeostasis and immune responses adds an extra layer of complexity to the fibrotic process and highlights the multifaceted functions of NEK7.

In the context of liver disease, where oxidative damage and chronic inflammation synergize to drive fibrosis, the protective role of NEK7 may represent a key defensive mechanism evolved to mitigate cellular stress. These findings invite future investigation into the modulation of NEK7 by metabolic and environmental factors, potentially linking lifestyle and dietary influences to mitochondrial resilience and liver health.

While the study presents compelling evidence delineating NEK7’s role, several questions remain open. It will be essential to determine the upstream signals that regulate NEK7 expression and activity within hepatic cells under fibrotic stimuli. Furthermore, understanding the tissue-specific nuances of NEK7 function and its broader interactome within the mitochondrial milieu could reveal additional targets for comprehensive intervention strategies.

As a broader perspective, the identification of NEK7 as a kinase intricately involved in mitochondrial electron transport challenges the traditional view of kinases as predominantly cytoplasmic or nuclear regulators. This research exemplifies the emerging appreciation of mitochondrial kinases as critical modulators of organelle function, paving the way for a new frontier in mitochondrial biology focused on enzymatic regulation of metabolic complexes.

Sun et al.’s pioneering work offers a vivid example of translational research, integrating molecular biology, structural biochemistry, and pathophysiology to tackle a daunting clinical challenge. By illuminating the intricate molecular interplay between NEK7 and SDHB, their study furnishes a detailed map of respiratory chain regulation that could inform drug discovery and personalized medicine approaches for liver fibrosis.

In conclusion, the insights uncovered establish a paradigm wherein NEK7 serves as a molecular gatekeeper, adeptly maintaining respiratory chain electron transport homeostasis to forestall liver fibrosis. This discovery not only enhances our fundamental understanding of mitochondrial biology in hepatic pathophysiology but also propels NEK7 to the forefront of emerging antifibrotic therapies. As liver fibrosis continues to pose a major health threat worldwide, innovations borne from such molecular elucidations offer hope for effective intervention and improved patient outcomes.

Subject of Research: Molecular mechanisms underlying mitochondrial respiratory chain regulation and its role in liver fibrosis.

Article Title: NEK7 couples SDHB to orchestrate respiratory chain electron transport homeostasis that impedes liver fibrosis.

Article References:
Sun, Z., Sun, L., Hua, H. et al. NEK7 couples SDHB to orchestrate respiratory chain electron transport homeostasis that impedes liver fibrosis. Nat Commun 16, 10751 (2025). https://doi.org/10.1038/s41467-025-65790-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65790-0

At a molecular level, TGF-β exerts its fibrotic influence through intricate signaling pathways. The canonical SMAD-dependent pathway is initiated upon TGF-β ligand binding to serine/threonine kinase receptors, TβRII and TβRI (also known as ALK5). This triggers phosphorylation cascades involving SMAD2 and SMAD3, which form complexes with SMAD4 and translocate to the nucleus, where they regulate the transcription of fibrogenic genes, including those encoding collagen and other extracellular matrix components. This pathway remains tightly regulated by inhibitory SMAD proteins, such as SMAD6 and SMAD7, which act as critical brakes within the signaling network to prevent unchecked fibrosis.

Parallel to the canonical route, TGF-β activates multiple SMAD-independent pathways that amplify its fibrotic effects. These include the PI3K/Akt axis, mitogen-activated protein kinases (MAPKs) such as ERK, JNK, and p38, and TAK1 kinase. The convergence of these pathways modulates various cellular functions, including hepatic stellate cell proliferation, survival, epithelial-mesenchymal transition, and matrix remodeling. This multifaceted signaling complexity contributes to the robustness and redundancy of fibrogenic responses, posing significant barriers to therapeutic targeting without eliciting substantial off-target effects.

The therapeutic landscape aiming to disrupt TGF-β signaling is diverse and evolving. One primary avenue involves the use of monoclonal antibodies that directly neutralize TGF-β ligands, thus preventing receptor engagement and subsequent downstream signaling. Agents such as Fresolimumab (GC1008) and CAT-192 have demonstrated efficacy in fibrotic conditions outside of hepatology, yet their translation to liver fibrosis remains in early phase clinical evaluations. Concerns regarding systemic blockade of TGF-β stem from its vital roles in immune regulation and tissue homeostasis, which can be compromised leading to adverse effects.

Advancing precision in intervention, small-molecule inhibitors targeting the kinase activity of TGF-β receptors have garnered significant interest. Galunisertib (LY2157299) is a prototypic inhibitor of the TβRI receptor kinase domain that impedes SMAD phosphorylation, thereby curtailing downstream fibrotic gene expression. Clinical trials indicate that Galunisertib not only exhibits pronounced anti-fibrotic potential but may also improve survival outcomes in hepatocellular carcinoma patients, highlighting its dual antitumor and antifibrotic capabilities. Complementary molecules such as Vactosertib and integrin inhibitors like PLN-1474 further delineate the therapeutic diversity by modulating specific receptor interactions and activation states.

Emerging molecular modalities employ antisense oligonucleotides (ASOs) to selectively degrade TGF-β mRNA, thus reducing protein synthesis. Trabedersen (AP-12009) exemplifies this strategy, offering exquisite specificity with the potential for reduced systemic toxicity. Nonetheless, ASO-based therapies remain in nascent stages of research for liver fibrosis, with ongoing investigations required to clarify their pharmacodynamics, delivery mechanisms, and clinical efficacy.

Another therapeutic concept revolves around indirect suppression of TGF-β signaling through downstream pathway inhibition. Drugs such as Pirfenidone and its derivative Hydronidone have shown promise, with the latter demonstrating significant improvements in liver fibrosis markers when administered alongside antiviral agents like entecavir in chronic hepatitis B patients. These compounds likely modulate the fibrotic milieu by attenuating SMAD activity and associated proinflammatory cascades, underscoring the potential benefits of combination regimens.

An intriguing and rapidly expanding area of research is the potential of Traditional Chinese Medicine (TCM) in targeting liver fibrosis. Numerous phytochemicals, including alkaloids such as Piperine and Sinomenine, flavonoids like Chrysin and Quercetin, and terpenoids exemplified by Limonin and Andrographolide, exhibit anti-fibrotic effects through modulation of the TGF-β pathway. These compounds offer multifaceted mechanisms with lower toxicity profiles, presenting valuable leads for drug development. However, standardized clinical evaluations remain necessary to transition these agents from bench to bedside effectively.

Despite these advances, the clinical translation of TGF-β-targeting agents faces profound challenges. The paradoxical role of TGF-β as a tumor suppressor in early disease stages versus a fibrosis and tumor promoter in later stages complicates therapeutic timing and patient selection. Moreover, systemic inhibition can disrupt critical physiological functions, including immune tolerance and tissue repair, leading to autoimmunity and impaired healing. Such risks necessitate the development of highly selective, isoform-specific inhibitors or targeted delivery systems, potentially through nanoparticle technologies, to minimize off-target effects.

Future directions emphasize the integration of combination therapies aimed at concurrently modulating multiple fibrogenic pathways. Co-targeting TGF-β alongside complementary signaling networks may enhance antifibrotic efficacy, overcome resistance mechanisms, and mitigate adverse outcomes. Additionally, rigorous pharmacological characterization and clinical validation of TCM-derived compounds could enrich the therapeutic arsenal, capitalizing on their versatility and historical medicinal use.

Ultimately, the intricate understanding of TGF-β as a master regulator in liver fibrosis provides a blueprint for innovative therapeutic strategies. This comprehensive approach, supported by molecular insights, translational research, and natural product pharmacology, charts a promising pathway toward effective, targeted treatments capable of halting or reversing liver fibrogenesis. The advent of such therapies has the potential to revolutionize clinical management and patient prognosis in hepatic fibrosis and its sequelae.

Subject of Research: Liver Fibrosis and Transforming Growth Factor-Beta (TGF-β) Signaling Pathways
Article Title: Exploring the Therapeutic Potential of TGF-β Inhibitors for Liver Fibrosis: Targeting Multiple Signaling Pathways
News Publication Date: 15-Jul-2025
Web References: https://www.xiahepublishing.com/journal/jcth, http://dx.doi.org/10.14218/JCTH.2025.00029
Image Credits: Lingying Huang, Zhi Shang
Keywords: Fibrosis, Enzyme inhibitors

Liver fibrosis, characterized by the excessive accumulation of extracellular matrix proteins, results from chronic liver injury and poses a threat of progression to cirrhosis and hepatocellular carcinoma. Central to this fibrogenic process are HSCs, which, upon activation, transform into proliferative myofibroblast-like cells that secrete fibrotic components. Despite advances in understanding fibrogenesis, targeted therapies remain elusive, largely due to the complex molecular interplay underlying HSC activation. This study’s focus on microRNAs, especially miR-125a-5p, sheds light on novel regulatory mechanisms that could be harnessed to curb fibrotic progression.

MicroRNAs serve as key post-transcriptional regulators of gene expression, influencing diverse cellular processes. miR-125a-5p, in particular, has been implicated in cellular differentiation, proliferation, and apoptosis across various tissues, but its specific function within the hepatic fibrotic milieu had remained unclear until now. Through meticulous experimentation, Zhang and colleagues demonstrated that boosting miR-125a-5p levels in activated HSCs exerts a suppressive effect on their fibrogenic activity, offering a new dimension to fibrotic disease modulation.

Delving into the mechanistic underpinnings, the study elucidated that miR-125a-5p negatively regulates the Transforming Growth Factor-beta (TGF-β) signaling axis, a master regulator of fibrogenesis. The TGF-β pathway exerts potent profibrotic effects via Smad2 and Smad3 phosphorylation, which facilitates extracellular matrix gene transcription. Overexpression of miR-125a-5p was observed to attenuate Smad2/3 activation, thereby reducing the fibrotic gene expression that drives HSC-mediated matrix deposition. This molecular intervention disrupts the pathological feedback loop sustaining fibrosis.

Simultaneously, the researchers uncovered that miR-125a-5p enhances autophagy, a cellular degradation pathway with a well-documented role in maintaining hepatic homeostasis and restraining fibrogenic activity. Autophagy enables cellular remodeling and clearance of damaged organelles, hence mitigating the stress signals that typically provoke HSC activation. By promoting autophagic flux, miR-125a-5p indirectly inhibits fibrotic progression, suggesting a dual mechanism by which it combats liver fibrosis – both through direct signaling modulation and cellular housekeeping functions.

Methodologically, the team employed state-of-the-art molecular biology tools, including gene overexpression and silencing techniques in cultured primary HSCs, alongside in vivo fibrosis mouse models. These robust approaches allowed for detailed dissection of miR-125a-5p’s functional impact at cellular and organismal levels. Histological analyses confirmed reduced collagen deposition and fibrotic markers in miR-125a-5p overexpressing subjects, correlating molecular findings with tangible disease amelioration.

One of the study’s striking revelations is the therapeutic potential of miR-125a-5p mimics as prospective antifibrotic agents. Unlike existing treatment modalities that primarily focus on symptom management or inhibiting single fibrogenic factors, miR-125a-5p-based therapies could simultaneously dampen profibrotic signaling and bolster protective autophagy pathways. This dual-target approach is anticipated to yield higher efficacy and better clinical outcomes in patients with advanced liver fibrosis and cirrhosis.

The implications of these findings extend beyond liver fibrosis alone. Given the conserved nature of TGF-β signaling and autophagy across fibrotic diseases in various organs, miR-125a-5p emerges as a candidate molecule with broader antifibrotic applications. The study encourages future exploration into miR-125a-5p’s role in pulmonary, renal, and cardiac fibrosis, potentially catalyzing a paradigm shift in how these pervasive diseases are tackled.

Moreover, the research underscores the importance of microRNAs as master controllers in pathological tissue remodeling. The intricate balance maintained by miR-125a-5p between cellular activation and autophagic clearance exemplifies the complex interplay central to tissue repair and fibrosis. Targeting such regulators could surpass the limitations of strategies aimed at downstream effectors, offering more comprehensive disease control.

The authors acknowledge that while the findings are compelling, translational barriers remain before miRNA-based therapeutics can enter clinical practice. Issues including delivery specificity, off-target effects, and long-term safety require thorough investigation. Nonetheless, advancing nanoparticle delivery systems and liver-targeted vectors provide an optimistic outlook for feasible clinical application of miR-125a-5p modulation.

Importantly, this study encourages revisiting the fibrogenic cascade with an integrated perspective, considering both signal transduction and cellular autophagy. This holistic understanding is crucial for designing multifaceted interventions that effectively resolve fibrosis rather than merely halt its progression. Zhang et al.’s work serves as a blueprint for such integrative efforts, combining molecular biology with pathophysiological insights.

Future research directions emerging from this work include deciphering the upstream stimuli regulating miR-125a-5p expression in hepatic tissue under fibrotic stress. Uncovering how environmental, metabolic, or inflammatory cues impact miR-125a-5p dynamics could reveal novel preventive strategies. Likewise, elucidating cross-talk between miR-125a-5p and other microRNAs or epigenetic modifiers could deepen comprehension of fibrosis plasticity.

In conclusion, the identification of miR-125a-5p as a crucial inhibitory factor of HSC activation and liver fibrosis through modulation of TGF-β/Smad2/3 signaling and autophagy opens new avenues for therapeutic innovation. This advancement heralds a promising era where precision molecular therapies could transform clinical management of chronic liver diseases. As the burden of fibrosis-associated conditions continues to rise worldwide, such pioneering research represents a beacon of hope for millions affected by debilitating and often fatal fibrotic disorders.

Subject of Research: MicroRNA regulation of hepatic stellate cell activation and liver fibrosis.

Article Title: Overexpression miR-125a-5p inhibits HSCs activation and alleviates liver fibrosis through TGF-β/Smad2/3 signaling pathway and autophagy.

Article References:
Zhang, C., Zhao, Y., Yan, H. et al. Overexpression miR-125a-5p inhibits HSCs activation and alleviates liver fibrosis through TGF-β/Smad2/3 signaling pathway and autophagy. Cell Death Discov. 11, 419 (2025). https://doi.org/10.1038/s41420-025-02694-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02694-4